Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who had ongoing (persistent) atrial fibrillation (an irregular heart rhythm) before undergoing a heart procedure to correct the rhythm (either catheter ablation or cardioversion)
- Group 1 (Cases): People whose heart pumping function was weakened (measured at 40% or below) while their heart rate was controlled during atrial fibrillation, and whose heart function fully recovered (to 55% or above) after their rhythm procedure, with no return of atrial fibrillation and no new or increased heart failure medications started
- Group 2 (Negative controls): People whose heart pumping function was normal (55% or above) during atrial fibrillation before their rhythm procedure
- Group 3 (Positive controls): People whose heart pumping function was weakened (40% or below) during atrial fibrillation before their rhythm procedure, and whose heart pumping function remained weakened (40% or below) after the procedure, with no change in heart failure medications and no return of atrial fibrillation
Who may not be able to join:
- People whose weakened heart function had a known alternative cause, such as a heart muscle condition that existed before the atrial fibrillation diagnosis, a primary heart valve problem, or an inherited heart muscle condition
- People who were pregnant during their atrial fibrillation or within the 12 months before their heart function became weakened
- People who drink more than 21 units of alcohol per week
- People with a history of receiving chemotherapy treatments known to be harmful to the heart
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shohreh Honarbakhsh, MBBS, PhD, Queen Mary University of London
Phone: +44(0) 20 3465 5398
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
DCM gene prevalence relative to negative control
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.